(Q33410392)

English

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

Shigeru Iida

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Reiko Kuni-Kamochi

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Katsuhiro Mori

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hirofumi Misaka

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Miho Inoue

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Akira Okazaki

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kenya Shitara

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mitsuo Satoh

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

18 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-9-58

0 references

Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Engineered antibody Fc variants with enhanced effector function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Profiling analysis of oligosaccharides in antibody pharmaceuticals by capillary electrophoresis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

History of antibody therapy for non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Rituximab (Rituxan/MabThera): the first decade (1993-2003).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Clinical Experience with Trastuzumab (Herceptin)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Renaissance of cancer therapeutic antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Structural studies on IgG oligosaccharides of patients with primary Sjögren's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

The ErbB receptor family: a therapeutic target for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Improving the efficacy of antibody-based cancer therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Mechanism of action of anti-HER2 monoclonal antibodies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Comparability testing of a humanized monoclonal antibody (Synagis) to support cell line stability, process validation, and scale-up for manufacturing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

Evaluation of monoclonal antibodies having specificity for human IgG subclasses: results of the 2nd IUIS/WHO collaborative study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649154

14 July 2018

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-58

21 January 2018

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-58

21 January 2018

Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-58

21 January 2018

A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-58

21 January 2018

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-58

21 January 2018

Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-58

21 January 2018

Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-58

21 January 2018

Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-58

21 January 2018

IgG subclass concentrations in certified reference material 470 and reference values for children and adults determined with the binding site reagents

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-58

21 January 2018

Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-58

21 January 2018

Monoclonal antibody successes in the clinic

1 reference

https://pubmed.ncbi.nlm.nih.gov/19226457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19226457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/19226457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

https://pubmed.ncbi.nlm.nih.gov/19226457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structural and numerical variations of the carbohydrate moiety of immunoglobulin G

1 reference

https://pubmed.ncbi.nlm.nih.gov/19226457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns

1 reference

https://pubmed.ncbi.nlm.nih.gov/19226457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of oligosaccharides of human IgG from serum of leukemia patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19226457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19226457

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-9-58

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33410392&oldid=1536348214"